Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinoma.


One hundred four patients with advanced colon carcinoma were treated with mitoxantrone 5 mg/m2 I.V. weekly. The patients were stratified into two groups: prior chemotherapy and no prior chemotherapy. Only one partial response was noted in the prior treatment category. 


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics